Trial reportShock (Augusta, Ga.)2026
Clinical and Immunologic Effects of Extracorporeal Cytokine Removal in Patients with Septic Shock: A Randomized Controlled Trial.
Trial report in Shock (Augusta, Ga.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune dysregulation and excessive cytokine release characterize the early phase of septic shock. Extracorporeal hemoadsorption with the CytoSorb device aims to restore immune balance by removing inflammatory mediators. Currently, clinical benefits remain uncertain.
methodsIn a single-center randomized controlled trial, 31 adult patients with septic shock, extracorporeal circuit, and interleukin-6 >500 pg/mL were included. The control group received standard care according to sepsis guidelines. The intervention group received standard care plus CytoSorb hemoadsorption. The primary outcome was the cumulative norepinephrine dose over 72 hours. Secondary outcomes included clinical and immunological endpoints.
resultsBetween February 2022 and July 2023, 58 patients with septic shock and hyperinflammation were screened for study inclusion. Seventeen patients were randomized to the control group, and 14 patients received extracorporeal cytokine removal. Hemoadsorption started within 24 hours after the onset of septic shock in 93% of cases. The cumulative norepinephrine dose in 72 hours was 78 mg (52.7-117.8 mg) in the control group and 100.7 mg (66.4-190.8 mg) with extracorporeal cytokine removal ( P = 0.09). The total vasopressor dose per hour alive in the first 72 hours was significantly lower in the control group compared with extracorporeal hemoadsorption (1.2 mg, 0.8-2.0 mg vs . 2.5 mg, 1.7-3.3 mg; P = 0.0053). Survival at 48 hours (100%, n = 17/17 vs . 64 %, n = 9/14; P = 0.01) and 72 hours (94%, n = 16/17 vs . 57%, n = 8/14; P = 0.03) after onset of septic shock was higher in the control group. Intensive care unit mortality, length of stay, duration of septic shock, and other clinical outcomes did not differ between the groups. The humoral immune response, including pro- and anti-inflammatory cytokines, was similar between groups. Compared with controls, patients with extracorporeal cytokine removal had significantly lower lymphocyte percentages during the first 3 days of septic shock (6.2%, 5.0% - 17.4% vs. 2.5%, 2.1% - 5.6%; P = 0.04), whereas leukocyte and lymphocyte subsets as well as cytotoxic capacities were not altered by hemoadsorption.
conclusionsEarly initiation of extracorporeal hemoadsorption in patients with septic shock did not improve vasopressor requirements or clinical outcomes, and no effects on the immune response were observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.